On Monday, November 9th,the CEO of Pfizer announced positive early results from its coronavirus vaccine trial, citing an over 90% effectiveness rate during its first phase of clinical trials. This is truly monumental news of worldwide significance. This fact has renewed hope throughout the country, indeed throughout the world, that we were finally coming closer to achieving a response to this deadly Pandemic. We at The SASSI Institute maintain our fervent hopes that in light of the over 100,000 daily national cases that have now become the norm, as a country and internationally, we will soon be able to eradicate this unfathomably terrible disease.
Given the recent spikes, like so many other businesses throughout the country, we recently had to again minimize our in-office time for all staff, including our shipping department. Nevertheless, all of our departments are open for business, and we want to reassure you that we will ship your products out on time, and as promised. We also want to remind you that we maintain our schedule of a December 1st SASSI Adolescent-3 release and that we have several articles in submission while we await their scientific review. Please contact our Customer Service team for pre-ordering information, and/or our Training Department for our upcoming training schedules.
I am delighted to announce that our Board of Directors and management team want to assure you that given this calamitous year, and in the hopes of giving our customer base a hand-up, we will not be raising prices in 2021. In fact, if you are experiencing financial difficulties, please contact our Customer Service Team and/or our Training team. They are more than willing to make suitable payment arrangements and offer their assistance during these difficult times.
We sincerely hope that you, your families, and colleagues remain safe. We remain confident that better times lie ahead!
Our Team at the Institute has been working tirelessly on a two-year research project to bring you an updated adolescent instrument that is validated against the DSM-5 diagnostic criteria. Our research has produced multiple publications and allowed the SASSI-A3 to include some new features, including a brief scale, Prescription Drug (Rx), to accurately identify teens likely to be abusing prescription medications. The updated version also includes new subtle items to reflect current teen alcohol and drug use patterns, as well as several updated questions using contemporary teen verbiage, and additional Face Valid items to identify symptoms in the DSM-5. The instrument also distinguishes likely Substance Use Disorder (SUD) from other psychological disorders; thus, the SASSI-A3 can accurately identify the presence and the absence of SUD, even when other psychological symptoms are present.
The SASSI-A3 will be available through SASSI Online immediately upon release and SASSI Online users can begin using it immediately on December 1st. Paper & Pencil product will be available for pre-order starting November 1st, with our first shipment of SASSI-A3 product/s scheduled for December 4th. After December 1st, the Adolescent SASSI-A2 Paper & Pencil material will remain available for purchase for a limited time, or while supplies last.
We wanted to provide you some important SASSI updates. We’re excited to announce that the research findings on the adolescent SASSI-A3 have been published! Within the coming weeks and next few months, we will be concentrating our efforts on publishing the SASSI-A3 instrument, which similarly to the adult screening tool, now includes a prescription drug scale and greater sensitivity to opioids and prescription medications. The updated instrument will available on our online platform immediately on the release date. We will provide additional details and pre-ordering information as soon as we have a confirmed availability date. You can read the published finding here: Validity of the Adolescent Substance Abuse Screening Inventory-3 (SASSI-A3). We also expect to publish other manuscripts examining co-occurring disorders among some of these adolescents; and the increase and dangers of Vaping as a drug source for them and adults, which has increased dramatically in recent years. These manuscripts are in submission and we hope to have them published by year end as well.
On another note, despite wonderful advances in securing possible cures and vaccines, COVID-19 clinical trials, and worldwide collaboratives to address this virus, the unfortunate reality is that the case numbers continue to climb and sadly, the death toll continues to rise. This has forced many states and local governments, and even the federal government, to change well thought initiatives and plans, and even back-track on some of the openings and relaxing of public health statutes. As a result, many private practitioners and even some long-standing programs have had to continue furloughing operations, or sadly cease operating altogether. With even greater sadness, we have heard multiple reports from the substance abuse, treatment, and correctional field/s about the loss of family, colleagues and friends to this devastating disease, and our hearts and prayers continue to go out to their families.
The SASSI Institute remains committed to helping you stay connected and feel supported during this period of uncertainty. We will be informing you of developments as they occur on our end. But for now, please accept heartfelt wishes from all of us, that you and your families remain safe.
We will get through this together!
The SASSI Institute conducted a validation project on the accuracy of the adolescent SASSI substance use screening measure with respect to the most current nationally accepted diagnostic standards for substance use disorders, the Diagnostic and Statistical Manual of Mental Disorders diagnostic criteria (DSM-5). We are delighted to report that our data analyses is complete and presently we are preparing our findings for peer review submission and subsequent publication and dissemination.
Decision rules were formulated that would provide a good degree of accuracy using our development sample. Yet, the crucial issue is whether the SASSI-A3 scoring rules would be accurate when applied to a sample not used in formulating the decision rules. That is, how well does the SASSI-A3 cross-validate? When tested, we are pleased to report that the SASSI-A3 decision rules on the cross-validation sample results indicated an overall accuracy of 93.41%, 15.01% gain in sensitivity, 0.83% loss in specificity, and 9.75% gain in overall accuracy!
When released, SASSI-A3 will now include updated language reflecting current teen drug trends, a prescription drug abuse scale, as well as additional items. Once the publication review process is finalized, we are looking forward to making this updated tool available to professionals in the field.
We want to once again acknowledge and thank all the individuals and organizations who provided us with their valuable contributions.
Scarlett Baker, A.A. – SASSI A-3 Project Director, and SASSI Institute Director of Training